Silencing of FOS-like antigen 1 represses restenosis via the ERK/AP-1 pathway in type 2 diabetic mice. (6th December 2021)

• Record Type: Journal Article
• Authors: Zhou, Chaoxi; Wang, Fujun; Ma, Hongfang; Xing, Na; Hou, Lin; Du, Yaping; Ding, Haixia
• Is Part Of: Diabetes & vascular disease research. Volume 18:Number 6(2021)
• Publication Date: 2021-12-06
• Subjects: type 2 diabetes -- restenosis -- vascular smooth muscle cell -- FOSL1 -- ERK/AP-1 pathway; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/14791641211058855
• Languages: English
• ISSNs: 1479-1641

Abstract

Restenosis is a major limiting factor for a successful outcome in type 2 diabetes (T2D) patients undergoing percutaneous coronary intervention (PCI). The aim of this study is to explore the role and regulatory mechanism of FOS-like antigen 1 (FOSL1) in restenosis in T2D. A T2D with restenosis mouse model was established by the combination of high-fat diet and streptozotocin injection and by wire-injury. High glucose (HG)-treated vascular smooth muscle cells (VSMCs) were used to mimic T2D in vitro. The results of quantitative real time PCR and western blotting demonstrated that the expression of FOSL1 was increased not only in T2D mice or HG-induced VSMCs, but also in T2D mice that underwent wire-injury. HE staining revealed that FOSL1 knockdown significantly reduced the intimal/media ratio of T2D mice after wire-injury. Silencing of FOSL1 reversed the promoting effects of HG treatment on viability, migration and inflammation reactions, and the inhibiting effect on the apoptosis of VSMCs. Inhibition of ERK/AP-1 pathway obtained similar patterns in HG-induced VSMCs. The activation of ERK/AP-1 pathway reversed the influence of FOSL1 knockdown on HG-induced VSMCs. Our findings indicate that silencing of FOSL1 may suppress restenosis via regulation of the ERK/AP-1 pathway in T2D mice, pointing out a potential therapeutic target to prevent restenosis in T2D.